Trial Profile
A Phase 1/2 Open-Label Study to Assess the Safety, Pharmacokinetics, and Anti-Tumor Activity of Oral EPI-506 in Patients With Metastatic Castration-Resistant Prostate Cancer
Status:
Discontinued
Phase of Trial:
Phase I/II
Latest Information Update: 07 Dec 2021
Price :
$35
*
At a glance
- Drugs Ralaniten acetate (Primary)
- Indications Adenocarcinoma; Prostate cancer
- Focus Adverse reactions; First in man; Proof of concept; Therapeutic Use
- Sponsors ESSA Pharma
- 29 Nov 2021 Results assessing the safety and pharmacokinetic profile of EPI-506 and determine the recommended phase 2 dosing regimen as well as evaluate preliminary anti-tumor activity, published in the Investigational New Drugs.
- 16 Feb 2019 Results assessing EPI-506's metabolic vulnerabilities by analysing patient plasma samples, presented at the 2019 Genitourinary Cancers Symposium.
- 11 Feb 2019 According to an ESSA Pharma media release, data from the study has been selected for a poster presentation at the upcoming 2019 Genitourinary Cancers Symposium.